What amount sold does Swep Bio, Inc. report in Form D filings?

The latest linked filings report $2.5M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Swep Bio, Inc.'s most recent SEC filing?

Swep Bio, Inc.'s most recent Form D filing was on 2026-10-29.

How many investors does Swep Bio, Inc. have?

The most recent Form D filing lists 1 investor(s).

What type of securities does Swep Bio, Inc. offer?

Swep Bio, Inc.'s SEC Form D filings indicate equity offerings.

Swep Bio, Inc.

CIK: 0002159106·Biotechnology·SCARSDALE, NY·Corporation·Founded 2026

Reported Sold

$2,499,989

Total Filings

Identified Offerings

Last Filed

Oct 29, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Oct 29, 2026Form D — New notice

Reported sold: $2,499,989 · Target: $4,999,976

Rule 506(b)·1 investor

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$2,499,989

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Goran Mikael Dolsten

Related Person

Appears on 1 filing

Karl Erik Emanuel Berglund

Related Person

Appears on 1 filing

Lovisa Backemar

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Oct 29, 2026	New	$4,999,976	$2,499,989	1

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Hypercell Technologies Inc.

Biotechnology

Offering target: $4,423,378

Filed Oct 14, 2026